Cabazitaxel, a novel chemotherapeutic alternative for drug-resistant hepatocellular carcinoma

The prognosis of advanced hepatocellular carcinoma (HCC) patients remains extremely poor, partially due to the development of acquired resistance to sorafenib and chemotherapy. Cabazitaxel, a semisynthetic taxane, has been approved for the therapy of docetaxel-resistant prostate cancer. However, no...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Cancer Res
Autors principals: Chen, Ronggao, Cheng, Qiyang, Owusu-Ansah, Kwabena Gyabaah, Chen, Jun, Song, Guangyuan, Xie, Haiyang, Zhou, Lin, Xu, Xiao, Jiang, Donghai, Zheng, Shusen
Format: Artigo
Idioma:Inglês
Publicat: e-Century Publishing Corporation 2018
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6079161/
https://ncbi.nlm.nih.gov/pubmed/30094102
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars